| Printer Friendly Version |
| Chronic Inflammatory Diseases - Commercial and Healthcare Reform | |
|---|---|
| Number: J-0558 | Category: Prior Authorization |
|
Line(s) of Business:
Commercial |
Benefit(s):
Commercial Prior Authorization (1. or 2.)
Quantity Limits (1., 2., 3., or 4.)
Healthcare Reform: Not Applicable |
|
Region(s):
All |
Additional Restriction(s):
None |
| Drugs Products |
|
| FDA-Approved Indications: |
|
| Background: |
|
| Approval Criteria | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Table 1. Summary of Preferred Products Given by Oral or Subcutaneous (SC) Administration by Indication
1 Actemra SC will require a trial of Humira first within the Polyarticular Juvenile Idiopathic Arthritis (PJIA) indication only. 2 Orencia SC will now require a trial of two step 1 (Enbrel, Humira) or step 2 (Actemra) agents. 3 Enbrel will require a trial of Humira for patients greater than or equal to 18 years of age within the plaque psoriasis indication only. 4 Xeljanz XR is not indicated in ulcerative colitis (UC) and is not addressed within this indication.
I. Actemra (tocilizumab) A. Initial Authorization 1. Rheumatoid Arthritis When a benefit, coverage of Actemra SC may be approved for rheumatoid arthritis (RA) when all of the following criteria are met (a. and b.): a. Actemra SC is to be used in adult patients with moderately to severely active rheumatoid arthritis (RA). b. Treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. 2. Giant Cell Arteritis When a benefit, coverage of Actemra SC may be approved for giant cell arteritis (GCA) when all of the following criteria are met (a. and b.): a. Actemra SC is to be used adult patients with giant cell arteritis (GCA). b. Treatment with at least one systemic corticosteroid (e.g., prednisone) was ineffective or not tolerated, or all corticosteroids are contraindicated. 3. Polyarticular Juvenile Idiopathic Arthritis When a benefit, coverage of Actemra SC may be approved for polyarticular juvenile idiopathic arthritis (PJIA) when all of the following criteria are met (a., b., and c.): a. Actemra SC is to be used for the treatment of polyarticular juvenile idiopathic arthritis (PJIA) in patients ≥ 2 years of age. b. The patient meets one of the following conditions (i., ii., iii., or iv.): i. The patient has tried one other agent for this condition (e.g., methotrexate [MTX], sulfasalazine, leflunomide, or a nonsteroidal anti-inflammatory drug [NSAID]). ii. The patient will be starting on Actemra SC concurrently with methotrexate (MTX), sulfasalazine, or leflunomide. iii. The patient has an absolute contraindication to methotrexate (MTX) [e.g., pregnancy, breast feeding, alcoholic liver disease, immunodeficiency syndrome, blood dyscrasias], sulfasalazine, or leflunomide. iv. The patient has aggressive disease, as determined by the prescribing physician. c. Treatment with Humira for the treatment of juvenile idiopathic arthritis (JIA) was ineffective or not tolerated (see Table 1) 4. Systemic Juvenile Idiopathic Arthritis When a benefit, coverage of Actemra SC may be approved for systemic juvenile idiopathic arthritis (SJIA) when the following criterion is met (a.): a. Actemra SC is to be used for the treatment of systemic juvenile idiopathic arthritis (SJIA) in patients ≥ 2 years of age.
B. Reauthorization When a benefit, reauthorization of Actemra SC may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
C. Quantity Limitations When prior authorization is approved, Actemra SC may be authorized in quantities as follows:
II. Cosentyx (secukinumab) A. Initial Authorization 1. Ankylosing Spondylitis When a benefit, coverage of Cosentyx may be approved for ankylosing spondylitis (AS) when all of the following criteria are met (a. and b.): a. Cosentyx is to be used for the treatment of adults with ankylosing spondylitis. b. Treatment with a nonsteroidal anti-inflammatory drug (NSAID) was ineffective or not tolerated, or all NSAIDs are contraindicated. 2. Psoriatic Arthritis When a benefit, coverage of Cosentyx may be approved for psoriatic arthritis (PsA) when one of the following criterion is met (a., b., or c.): a. Spinal or axial psoriatic arthritis (i. and ii.): i. For the treatment of adults with predominant spinal or axial psoriatic arthritis. ii. When treatment with at least one NSAID was ineffective or not tolerated or all NSAIDs are contraindicated. b. Psoriatic arthritis without spinal or axial disease (i. and ii.): i. For the treatment of adults with psoriatic arthritis without spinal disease. ii. When treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. c. Enthesitis and/or dactylitis associated psoriatic arthritis (i. and ii.): i. For the treatment of adults with active enthesitis and/or dactylitis associated with psoriatic arthritis ii. When treatment with (a. or b.): a. At least one NSAID or a local glucocorticoid injection was ineffective or not tolerated. b. All NSAIDs and all local glucocorticoid injections are contraindicated. 3. Plaque Psoriasis, including Scalp Psoriasis When a benefit, coverage of Cosentyx may be approved for plaque psoriasis (PsO) when all of the following criteria are met (a. and b.): a. Cosentyx is to be used for the treatment of moderate to severe plaque psoriasis. b. One of the following criterion is met (i. or ii.): i. Treatment with phototherapy (e.g. PUVA, UVB) was ineffective or not tolerated. If member is not a candidate for phototherapy treatment (e.g. phototherapy is contraindicated due to history of lupus erythematosus, porphyria, or xeroderma pigmentosum), treatment with systemic therapy (e.g. methotrexate, cyclosporine) must have been ineffective or not tolerated, or all systemic therapies are contraindicated. ii. Treatment with systemic therapy (e.g. methotrexate, cyclosporine) was ineffective or not tolerated, or all systemic therapies are contraindicated.
B. Reauthorization When a benefit, reauthorization of Cosentyx may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
C. Quantity Limitations When prior authorization is approved, Cosentyx may be authorized in quantities as follows:
III. Enbrel (etanercept) A. Initial Authorization 1. Rheumatoid Arthritis When a benefit, coverage of Enbrel may be approved for rheumatoid arthritis (RA) when all of the following criteria are met (a. and b.): a. Enbrel is to be used for the treatment of adults with rheumatoid arthritis (RA). b. Treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. 2. Ankylosing Spondylitis When a benefit, coverage of Enbrel may be approved for ankylosing spondylitis (AS) when all of the following criteria are met (a. and b.): a. Enbrel is to be used in the treatment of adults with ankylosing spondylitis. b. Treatment with a nonsteroidal anti-inflammatory drug (NSAID) was ineffective or not tolerated, or all NSAIDs are contraindicated. 3. Juvenile Idiopathic Arthritis When a benefit, coverage of Enbrel may be approved for juvenile idiopathic arthritis (JIA) when all of the following criteria are met (a. and b.): a. Enbrel is to be used for the treatment of juvenile idiopathic arthritis in patients ≥ 2 years of age. b. Treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. 4. Psoriatic Arthritis When a benefit, coverage of Enbrel may be approved for psoriatic arthritis (PsA) when one of the following criterion is met (a., b., or c.): a. Spinal or axial psoriatic arthritis (i. and ii.): i. For the treatment of adults with predominant spinal or axial psoriatic arthritis. ii. When treatment with at least one NSAID was ineffective or not tolerated or all NSAIDs are contraindicated. b. Psoriatic arthritis without spinal or axial disease (i. and ii.): i. For the treatment of adults with psoriatic arthritis without spinal disease. ii. When treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. c. Enthesitis and/or dactylitis associated psoriatic arthritis (i. and ii.): i. For the treatment of adults with active enthesitis and/or dactylitis associated with psoriatic arthritis. ii. When treatment with (a. or b.): 1) At least one NSAID or a local glucocorticoid injection was ineffective or not tolerated. 2) All NSAIDs and all local glucocorticoid injections are contraindicated. 5. Plaque Psoriasis, adults When a benefit, coverage of Enbrel may be approved for chronic plaque psoriasis (PsO) when all of the following criteria are met (a., b., and c.): a. Enbrel is to be used for the treatment of adults 18 years of age and older with chronic plaque psoriasis. b. One of the following criteria are met (i. or ii.): i. Treatment with phototherapy (e.g. PUVA, UVB) was ineffective or not tolerated. If member is not a candidate for phototherapy treatment (e.g. phototherapy is contraindicated due to history of lupus erythematosus, porphyria, or xeroderma pigmentosum), treatment with systemic therapy (e.g. methotrexate, cyclosporine) must have been ineffective or not tolerated, or all systemic therapies are contraindicated. ii. Treatment with systemic therapy (e.g. methotrexate, cyclosporine) was ineffective or not tolerated, or all systemic therapies are contraindicated. c. When the following criterion is met (i.): i. Treatment with preferred biologic product (Humira) for plaque psoriasis was ineffective or not tolerated 6. Plaque Psoriasis, pediatrics When a benefit, coverage of Enbrel may be approved for pediatric patients with chronic plaque psoriasis (PsO) when all of the following criteria are met (a. and b.): a. Enbrel is to be used for the treatment of children > 4 but <18 years of age with chronic plaque psoriasis. b. One of the following criterion is met (i. or ii.): i. Treatment with phototherapy (e.g. PUVA, UVB) was ineffective or not tolerated. If member is not a candidate for phototherapy treatment (e.g. phototherapy is contraindicated due to history of lupus erythematosus, porphyria, or xeroderma pigmentosum), treatment with systemic therapy (e.g. methotrexate, cyclosporine) must have been ineffective or not tolerated, or all systemic therapies are contraindicated. ii. Treatment with systemic therapy (e.g. methotrexate, cyclosporine) was ineffective or not tolerated, or all systemic therapies are contraindicated.
B. Reauthorization When a benefit, reauthorization of Enbrel may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
C. Quantity Limitations When prior authorization is approved, Enbrel may be authorized in quantities as follows:
N/A=not applicable
IV. Humira (adalimumab) A. Initial Authorization 1. Rheumatoid Arthritis When a benefit, coverage of Humira may be approved for rheumatoid arthritis (RA) when all of the following criteria are met (a. and b.): a. Humira is to be used for the treatment of adults with rheumatoid arthritis (RA). b. Treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. 2. Ankylosing Spondylitis When a benefit, coverage of Humira may be approved for ankylosing spondylitis (AS) when all of the following criteria are met (a. and b.): a. Humira is to be used in the treatment of adults with ankylosing spondylitis. b. Treatment with a nonsteroidal anti-inflammatory drug (NSAID) was ineffective or not tolerated, or all NSAIDs are contraindicated. 3. Juvenile Idiopathic Arthritis When a benefit, coverage of Humira may be approved for juvenile idiopathic arthritis (JIA) when all of the following criteria are met (a. and b.): a. Humira is to be used for the treatment of juvenile idiopathic arthritis in patients ≥ 2 years of age. b. Treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. 4. Psoriatic Arthritis When a benefit, coverage of Humira may be approved for psoriatic arthritis (PsA) when one of the following criterion is met (a., b., or c.): a. Spinal or axial psoriatic arthritis (i. and ii.): i. For the treatment of adults with predominant spinal or axial psoriatic arthritis. ii. When treatment with at least one NSAID was ineffective or not tolerated or all NSAIDs are contraindicated. b. Psoriatic arthritis without spinal or axial disease (i. and ii.): i. For the treatment of adults with psoriatic arthritis without spinal disease. ii. When treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. c. Enthesitis and/or dactylitis associated psoriatic arthritis (i. and ii.): i. For the treatment of adults with active enthesitis and/or dactylitis associated with psoriatic arthritis. ii. When treatment with (1 or 2): 1) At least one NSAID or a local glucocorticoid injection was ineffective or not tolerated. 2) All NSAIDs and all local glucocorticoid injections are contraindicated. 5. Plaque Psoriasis When a benefit, coverage of Humira may be approved for chronic plaque psoriasis (PsO) when all of the following criteria are met (a. and b.): a. Humira is to be used for the treatment of adults with chronic plaque psoriasis. b. One of the following criteria are met (i. or ii.): i. Treatment with phototherapy (e.g. PUVA, UVB) was ineffective or not tolerated. If member is not a candidate for phototherapy treatment (e.g. phototherapy is contraindicated due to history of lupus erythematosus, porphyria, or xeroderma pigmentosum), treatment with systemic therapy (e.g. methotrexate, cyclosporine) must have been ineffective or not tolerated, or all systemic therapies are contraindicated. ii. Treatment with systemic therapy (e.g. methotrexate, cyclosporine) was ineffective or not tolerated, or all systemic therapies are contraindicated. 6. Crohn’s Disease, adults When a benefit, coverage of Humira may be approved for adult patients with Crohn’s disease (CD) when all of the following criteria are met (a. and b.): a. Humira is to be used in the treatment of adult patients with moderate to severe Crohn's disease. b. One of the following criterion is met (i. or ii.): i. Treatment with at least two immunosuppressants (e.g. corticosteroids, azathioprine, 6-mercaptopurine, or methotrexate) was ineffective or not tolerated, or immunosuppressants are contraindicated. ii. The member is currently pregnant. 7. Crohn’s Disease, pediatrics When a benefit, coverage of Humira may be approved for pediatric patients with Crohn’s disease (CD) when all of the following criteria are met (a. and b.): a. Humira is to be used in reducing the signs and symptoms of pediatric patients ≥ 6 years of age with moderate to severe Crohn's disease. b. Treatment with at least one immunosuppressant (e.g. corticosteroids, azathioprine, 6-mercaptopurine, or methotrexate) was ineffective or not tolerated, or immunosuppressants are contraindicated. 8. Ulcerative Colitis When a benefit, coverage of Humira may be approved for ulcerative colitis (UC) when one of the following criteria are met (a., b., or c.): a. Humira is to be used for treatment of adults with ulcerative colitis who have not responded to treatment with at least two immunosuppressants (e.g. corticosteroids, azathioprine, or 6-mercaptopurine). b. Humira is to be used to induce and maintain clinical remission in adult patients with moderate to severe ulcerative colitis who require continuous steroid therapy. c. Humira is to be used for treatment of a pregnant patient with ulcerative colitis. 9. Hidradenitis Suppurativa When a benefit, coverage of Humira may be approved for hidradenitis suppurativa (HS) when the following criterion is met (a.): a. Humira is to be used in the treatment of moderate to severe hidradenitis suppurativa. 10. Uveitis When a benefit, coverage of Humira may be approved for uveitis when all of the following criteria are met (a. and b.): a. Humira is to be used in the treatment of non-infectious intermediate, posterior or panuveitis. b. Treatment with at least two immunosuppressants (e.g. corticosteroids, azathioprine, 6-mercaptopurine) was ineffective or not tolerated, or immunosuppressants are contraindicated.
B. Reauthorization When a benefit, reauthorization of Humira may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
C. Quantity Limitations When prior authorization is approved, Humira pre-filled syringes may be authorized in quantities as follows:
V. Otezla (apremilast) A. Initial Authorization 1. Psoriatic Arthritis When a benefit, coverage of Otezla may be approved for psoriatic arthritis (PsA) when one of the following criterion is met (a., b., or c.): a. Spinal or axial psoriatic arthritis (i., ii., and iii.): i. For the treatment of adults with predominant spinal or axial psoriatic arthritis. ii. When treatment with at least one NSAID was ineffective or not tolerated or all NSAIDs are contraindicated. iii. Treatment with at least one preferred biologic product for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1). b. Psoriatic arthritis without spinal or axial disease (i., ii., and iii.): i. For the treatment of adults with psoriatic arthritis without spinal disease. ii. When treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. iii. Treatment with at least one preferred biologic product for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1). c. Enthesitis and/or dactylitis associated psoriatic arthritis (i., ii., and iii.): i. For the treatment of adults with active enthesitis and/or dactylitis associated with psoriatic arthritis. ii. When treatment with (a. or b.): 1) At least one NSAID or a local glucocorticoid injection was ineffective or not tolerated. 2) All NSAIDs and all local glucocorticoid injections are contraindicated. iii. Treatment with at least one preferred biologic product for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1). 2. Plaque Psoriasis When a benefit, coverage of Otezla may be approved for chronic plaque psoriasis (PsO) when all of the following criteria are met (a. and b.): a. Otezla is to be used for the treatment of adults with chronic plaque psoriasis. b. One of the following criterion is met (i. or ii.): i. Treatment with phototherapy (e.g. PUVA, UVB) was ineffective or not tolerated. If member is not a candidate for phototherapy treatment (e.g. phototherapy is contraindicated due to history of lupus erythematosus, porphyria, or xeroderma pigmentosum), treatment with systemic therapy (e.g. methotrexate, cyclosporine) must have been ineffective or not tolerated, or all systemic therapies are contraindicated. ii. Treatment with systemic therapy (e.g. methotrexate, cyclosporine) was ineffective or not tolerated, or all systemic therapies are contraindicated.
B. Reauthorization When a benefit, reauthorization of Otezla may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
VI. Skyrizi (risankizumab) A. Initial Authorization 1. Plaque Psoriasis When a benefit, coverage of Skyrizi may be approved for chornic plaque psoriasis (PsO) when all of the following criteria are met (a. and b.): a. Skyrizi is to be used for the treatment of adults with moderate to severe psoriasis. b. One of the following criterion is met (i. ii.): i. Treatment with phototherapy (e.g. PUVA, UVB) was ineffective or not tolerated. If member is not a candidate for phototherapy treatment (e.g. phototherapy is contraindicated due to history of lupus erythematosus, porphyria, or xeroderma pigmentosum), treatment with systemic therapy (e.g. methotrexate, cyclosporine) must have been ineffective or not tolerated, or all systemic therapies are contraindicated. ii. Treatment with systemic therapy (e.g. methotrexate, cyclosporine) was ineffective or not tolerated, or all systemic therapies are contraindicated. B. Reauthorization When a benefit, reauthorization of Skyrizi may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided. C. Quanitity Limitations When prior authorization is approved, Skyrizi may be authorized in quantities as follows:
N/A=not applicable *Patients diagnosed with Crohn’s disease may receive every 8-week dosing of Stelara. Patient Level Authorization (PLA) input - One (1) prefilled syringe every 42 days.
A. Initial Authorization 1. Psoriatic Arthritis When a benefit, coverage of Stelara may be approved for psoriatic arthritis (PsA) when one of the following criterion is met (a., b., or c.): a. Spinal or axial psoriatic arthritis (i. and ii.): i. For the treatment of adults with predominant spinal or axial psoriatic arthritis. ii. When treatment with at least one NSAID was ineffective or not tolerated or all NSAIDs are contraindicated. b. Psoriatic arthritis without spinal or axial disease (i. and ii.): i. For the treatment of adults with psoriatic arthritis without spinal disease ii. When treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated c. Enthesitis and/or dactylitis associated psoriatic arthritis (i. and ii.): i. For the treatment of adults with active enthesitis and/or dactylitis associated with psoriatic arthritis. ii. When treatment with (1 or 2): 1) At least one NSAID or a local glucocorticoid injection was ineffective or not tolerated. 2) All NSAIDs and all local glucocorticoid injections are contraindicated. 2. Plaque Psoriasis When a benefit, coverage of Stelara may be approved for chronic plaque psoriasis (PsO) when all of the following criteria are met (a. and b.): a. Stelara is to be used for the treatment of adolescents (12 years or older) or adults with chronic plaque psoriasis. b. One of the following criterion is met (i. or ii.): i. Treatment with phototherapy (e.g. PUVA, UVB) was ineffective or not tolerated. If member is not a candidate for phototherapy treatment (e.g. phototherapy is contraindicated due to history of lupus erythematosus, porphyria, or xeroderma pigmentosum), treatment with systemic therapy (e.g. methotrexate, cyclosporine) must have been ineffective or not tolerated, or all systemic therapies are contraindicated. ii. Treatment with systemic therapy (e.g. methotrexate, cyclosporine) was ineffective or not tolerated, or all systemic therapies are contraindicated. 3. Crohn’s Disease Patients Initiating Therapy with Stelara SC When a benefit, coverage of Stelara may be approved for adult patients with Crohn’s disease (CD) when all of the following criteria are met (a., b., and c.): a. Stelara is to be used in the treatment of adult patients with Crohn's disease. b. The patient received a single induction dose of Stelara IV within 2 months of initiating therapy with Stelara SC and achieved clinical response or remission. c. One of the following criterion is met (i., ii., or iii.): i. The member is currently pregnant. ii. Treatment with at least two immunosuppressants (e.g. corticosteroids, azathioprine, 6-mercaptopurine, or methotrexate) was ineffective or not tolerated, or immunosuppressants are contraindicated. iii. According to prescribing physician, the patient has experienced a previous intolerance to a TNF inhibitor or the patient has a relative contraindication to the use of a TNF inhibitor due to one of the following (1. or 2.): 1) Demyelinating disease 2) Heart failure Patients Currently Taking Stelara SC When a benefit, coverage of Stelara may be approved for adult patients with Crohn’s disease (CD) when all of the following criteria are met (a., b., and c.): a. Stelara is to be used in the treatment of adult patients with Crohn's disease. b. The patient has been established on Stelara SC for at least 90 days. c. Prescription claims history indicates at least a 90 day-supply was dispensed within the past 130 days (Eligible claims includes at least one paid claim that has not been reversed within the 130 day time period). i. NOTE: If prescription claims history is not available (e.g., patient is new to plan), provider attests that patient has been established on Stelara SC for at least 90 days.
B. Reauthorization When a benefit, reauthorization of Stelara may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
Dosing In addition, the criteria outlined above, documentation of member weight and prescribed Stelara dose consistent with dosing below is required: • Psoriasis (Adult) a. For patients weighing ≤100 kg (220 lbs), the recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. b. For patients weighing >100 kg (220 lbs), the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks. • Psoriasis (Adolescent 12 years and older) a. For patients weighing <60 kg (132 lbs), the recommended dose is 0.75 mg/kg initially and 4 weeks later, followed by 0.75 mg/kg every 12 weeks. b. For patients weighing 60 to 100 kg (220 lbs), the recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. c. For patients weighing >100 kg (220 lbs), the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks. • Psoriatic Arthritis a. The recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks For patients with co-existent moderate-to-severe plaque psoriasis weighing >100 kg (220 lbs), the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks. • Crohn's Disease a. Following a weight-based intravenous dose, the recommended dose is 90 mg 8 weeks following the intravenous dose, then every 8 weeks thereafter.
C. Quantity Limitations When prior authorization is approved, Stelara SC may be authorized in quantities as follows:
N/A=not applicable • *Patients diagnosed with Crohn’s disease may receive every 8-week dosing of Stelara. Patient Level Authorization (PLA) input - One (1) prefilled syringe every 56 days.
VIII. Tremfya (guselkumab) A. Initial Authorization 1. Plaque Psoriasis When a benefit, coverage of Tremfya may be approved for chronic plaque psoriasis (PsO) when all of the following criteria are met (a. and b.): a. Tremfya is to be used for the treatment of adults with moderate to severe psoriaasis. b. One of the following criterion is met (i. or ii.): i. Treatment with phototherapy (e.g. PUVA, UVB) was ineffective or not toerated. If member is not a candidate for phototherapy treatment (e.g. phototherapy is contraindicated due to history of lupus erythematosus, porphyria, or xeroderma pigmentosum) treatment with systemic therapy (e.g. methotrexate, cyclosporine) must have been ineffective or not tolerated, or all systemic therapies are contraindicated. ii. Treatment with systemic therapy (e.g. methotrexate, cyclosporine) was ineffective or not tolerated, or all systemic therapies are contraindicated. B. Reauthorization When a benefit, reauthorization of Tremfya may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided. c. Quantity Limitations When prior authorization is approved, Tremfya may be authorized in quantities as follows:
IX. Xeljanz (tofacitinib) A. Initial Authorization 1. Rheumatoid Arthritis When a benefit, coverage of Xeljanz or Xeljanz XR may be approved for rheumatoid arthritis (RA) when all of the following criteria are met (a. and b.): a. Xeljanz or Xeljanz XR is to be used for the treatment of adult patients with moderately to severely active rheumatoid arthritis. b. Treatment with methotrexate was ineffective or not tolerated. 2. Psoriatic Arthritis When a benefit, coverage of Xeljanz or Xeljanz XR may be approved for psoriatic arthritis (PsA) when all of the following criteria are met (a., b., or c.): a. Spinal or axial psoriatic arthritis (i. and ii.): i. For the treatment of adults with predominant spinal or axial psoriatic arthritis. ii. When treatment with at least one NSAID was ineffective or not tolerated or all NSAIDs are contraindicated. b. Psoriatic arthritis without spinal or axial disease (i., ii., and iii.): i. For the treatment of adults with psoriatic arthritis without spinal disease. ii. When treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. iii. Xeljanz or Xeljanz XR is used in combination with a nonbiologic DMARD. c. Enthesitis and/or dactylitis associated psoriatic arthritis (i. and ii.): i. For the treatment of adults with active enthesitis and/or dactylitis associated with psoriatic arthritis. ii. When treatment with (a. or b.): a. At least one NSAID or a local glucocorticoid injection was ineffective or not tolerated. b. All NSAIDs and all local glucocorticoid injections are contraindicated. 3. Ulcerative Colitis When a benefit, coverage of Xeljanz may be approved for adults patients with ulcerative colitis (UC) when all of the following criteria are met (a., b., and c.): a. Xeljanz is to be used to for the treatment of moderate to severe ulcerative colitis. b. Doses greater than 20 mg per day for Xeljanz will not be approved for ulcerative colitis. c. One of the following criterion is met (i. or ii.): i. Treatment with at least two immunosuppressants (e.g. corticosteroids, azathioprine, 6-mercaptopurine) was ineffective or not tolerated. ii. The member is currently pregnant.
B. Reauthorization When a benefit, reauthorization of Xeljanz or Xeljanz XR may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
X. Cimzia (certolizumab) A. Initial Authorization 1. Rheumatoid Arthritis When a benefit, coverage of Cimzia may be approved for rheumatoid arthritis (RA) when all of the following criteria are met (a. through d.): a. Cimzia is to be used for the treatment of adults with rheumatoid arthritis (RA). b. Cimzia is to be used alone or with methotrexate. c. Treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. d. Treatment with at least two preferred biologic products for the treatment of rheumatoid arthritis was ineffective or not tolerated (see Table 1). 2. Ankylosing Spondylitis When a benefit, coverage of Cimzia may be approved for ankylosing spondylitis (AS) when all of the following criteria are met (a., b., and c.): a. Cimzia is to be used for the treatment of adults with ankylosing spondylitis. b. Treatment with a nonsteroidal anti-inflammatory drug (NSAID) was ineffective or not tolerated, or all NSAIDs are contraindicated. c. Treatment with at least two preferred biologic products for the treatment of ankylosing spondylitis was ineffective or not tolerated (see Table 1). 3. Psoriatic Arthritis When a benefit, coverage of Cimzia may be approved for psoriatic arthritis (PsA) when one of the following criterion is met (a., b., or c.): a. Spinal or axial psoriatic arthritis (i., ii., and iii.): i. For the treatment of adults with predominant spinal or axial psoriatic arthritis. ii. When treatment with at least one NSAID was ineffective or not tolerated or all NSAIDs are contraindicated. iii. Treatment with at least two preferred biologic products for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1). b. Psoriatic arthritis without spinal or axial disease (i., ii., and iii.): i. For the treatment of adults with psoriatic arthritis without spinal disease. ii. When treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. iii. Treatment with at least two preferred biologic products for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1). c. Enthesitis and/or dactylitis associated psoriatic arthritis (i., ii., and iii.): i. For the treatment of adults with active enthesitis and/or dactylitis associated with psoriatic arthritis. ii. When treatment with at least (a. or b.): a. One NSAID or a local glucocorticoid injection was ineffective or not tolerated. b. All NSAIDs and all local glucocorticoid injections are contraindicated. iii. Treatment with at least two preferred biologic products for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1). 4. Crohn’s Disease When a benefit, coverage of Cimzia may be approved for adults patients with Crohn’s disease (CD) when all of the following criteria are met (a., b., and c.): a. Cimzia is to be used in the treatment of adult patients with Crohn's disease. b. One of the following criterion is met (i. or ii.): i. Treatment with at least two immunosuppressants (e.g. corticosteroids, azathioprine, 6-mercaptopurine, or methotrexate) was ineffective or not tolerated, or immunosuppressants are contraindicated. ii. The member is currently pregnant. c. Treatment with at least one preferred biologic product for the treatment of Crohn’s disease was ineffective or not tolerated (see Table 1). 5. Plaque Psoriasis When a benefit, coverage of Cimzia may be approved for chronic plaque psoriasis (PsO) when all of the following criteria are met (a., b., and c.): a. Cimzia is to be used for the treatment of adults with moderate to severe psoriasis. b. One of the following criterion is met (i. or ii.): i. Treatment with phototherapy (e.g. PUVA, UVB) was ineffective or not tolerated. If member is not a candidate for phototherapy treatment (e.g. phototherapy is contraindicated due to history of lupus erythematosus, porphyria, or xeroderma pigmentosum), treatment with systemic therapy (e.g. methotrexate, cyclosporine) must have been ineffective or not tolerated, or all systemic therapies are contraindicated. ii. Treatment with systemic therapy (e.g. methotrexate, cyclosporine) was ineffective or not tolerated, or all systemic therapies are contraindicated. c. Treatment with at least two preferred biologic products for the treatment of plaque psoriasis was ineffective or not tolerated (see Table 1). 6. Non-radiographic Axial Spondyloarthritis When a benefit, coverage of Cimzia may be approved for non-radiographic axial spondyloarhtritis (nr-axSpA) when all of the following criteria are met (a. and b.): a. Cimzia is to be used for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA). b. Treatment with at least two (2) nonsteroidal anti-inflammatory drugs (NSAIDs) were ineffective or not tolerated, or all NSAIDs are contraindicated. B. Reauthorization When a benefit, reauthorization of Cimzia may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
C. Quantity Limitations When prior authorization is approved, Cimzia may be authorized in quantities as follows:
• To note, starter package kits are coded for quantity level limitations of one (1) kit per 365 days.
XI. Kevzara (sarilumab) A. Initial Authorization 1. Rheumatoid Arthritis When a benefit, coverage of Kevzara may be approved for rheumatoid arthritis (RA) when all of the following criteria are met (a., b., and c.): a. Kevzara is to be used for the treatment of adults with rheumatoid arthritis (RA). b. Treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. c. Treatment with at least two preferred biologic products for the treatment of rheumatoid arthritis was ineffective or not tolerated (see Table 1).
B. Reauthorization When a benefit, reauthorization of Kevzara may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
C. Quantity Limitations When prior authorization is approved, Kevzara may be authorized in quantities as follows:
XII. Kineret (anakinra) A. Initial Authorization 1. Rheumatoid Arthritis When a benefit, coverage of Kineret may be approved for rheumatoid arthritis (RA) when all of the following criteria are met (a., b., and c.): a. Kineret is to be used for the treatment of adults with rheumatoid arthritis (RA). b. Treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. c. Treatment with at least two preferred biologic products for the treatment of rheumatoid arthritis was ineffective or not tolerated (see Table 1). 2. Neonatal-Onset Multisystem Inflammatory Disease When a benefit, coverage of Kineret may be approved for Neonatal-Onset Multisystem Inflammatory Disease (NOMID) when following criterion is met (a.): a. Kineret is to be used for the treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
B. Reauthorization When a benefit, reauthorization of Kineret may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
Dosing In addition, the criteria outlined above, documentation of member weight and prescribed Kineret dose consistent with dosing below is required: • Neonatal-Onset Multisystem Inflammatory Disease a. The recommended starting dose is 1-2 mg/kg daily. The dose can be individually adjusted to a maximum of 8 mg/kg daily. Kineret may be divided into twice daily dosing. A new syringe must be used for each dose and any unused portion after each dose should be discarded.
C. Quantity Limitations When prior authorization is approved, Kineret may be authorized in quantities as follows:
XIII. Olumiant (baricitinib) A. Initial Authorization 1. Rheumatoid Arthritis When a benefit, coverage of Olumiant may be approved for rheumatoid arthritis (RA) when all of the following criteria are met (a. through d.): a. Olumiant is to be used for treatment of adults with moderately to severely active rheumatoid arthritis (RA). b. Treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. c. Treatment with at least one tumor necrosis factor (TNF) antagonist therapy, including adalimumab (Humira), etanercept (Enbrel), golimumab (Simponi), and certolizumab (Cimzia), was ineffective or not tolerated. d. Treatment with at least two preferred biologic products for the treatment of rheumatoid arthritis was ineffective or not tolerated (see Table 1). i. If the member has tried and failed adalimumab (Humira) and etanercept (Enbrel), the member will not need to try and fail any additional preferred biologic products. ii. If the member has tried and failed either adalimumab (Humira) or etanercept (Enbrel), the member will need to try and fail one additional preferred biologic product.
B. Reauthorization When a benefit, reauthorization of Olumiant may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
XIV. Orencia (abatacept) A. Initial Authorization 1. Rheumatoid Arthritis When a benefit, coverage of Orencia subcutaneous (SC) may be approved for rheumatoid arthritis (RA) when all of the following criteria are met (a., b., and c.): a. Orencia SC is to be used in reducing the signs and symptoms and inhibiting the progression of structural damage in adults with moderate to severe active rheumatoid arthritis. b. Treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. c. Treatment with at least two preferred biologic products for the treatment of rheumatoid arthritis was ineffective or not tolerated (see Table 1). 2. Juvenile Idiopathic Arthritis When a benefit, coverage of Orencia SC may be approved for juvenile idiopathic arthritis (JIA) when all of the following criteria are met (a., b., and c.): a. Orencia SC is to be used for the treatment of juvenile idiopathic arthritis in patients ≥ 2 years of age. b. Treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. c. Treatment with at least two preferred biologic products for the treatment of juvenile idiopathic arthritis (JIA) was ineffective or not tolerated (see Table 1) 3. Psoriatic Arthritis When a benefit, coverage of Orencia SC may be approved for psoriatic arthritis (PsA) when one of the following criterion is met (a., b., or c.): a. Spinal or axial psoriatic arthritis (i., ii., and iii.): i. For the treatment of adults with predominant spinal or axial psoriatic arthritis. ii. When treatment with at least one NSAID was ineffective or not tolerated or all NSAIDs are contraindicated. iii. Treatment with at least two preferred biologic products for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1). b. Psoriatic arthritis without spinal or axial disease (i., ii., and iii.): i. For the treatment of adults with psoriatic arthritis without spinal disease. ii. When treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. iii. Treatment with at least two preferred biologic products for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1). c. Enthesitis and/or dactylitis associated psoriatic arthritis (i., ii., and iii.): i. For the treatment of adults with active enthesitis and/or dactylitis associated with psoriatic arthritis ii. When treatment with at least (a. or b.): a. One NSAID or a local glucocorticoid injection was ineffective or not tolerated b. All NSAIDs and all local glucocorticoid injections are contraindicated iii. Treatment with at least two preferred biologic products for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1)
B. Reauthorization When a benefit, reauthorization of Orencia SC may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
C. Quantity Limitations When prior authorization is approved, Orencia SC may be authorized in quantities as follows:
XV. Siliq (brodalumab) A. Initial Authorization 1. Plaque Psoriasis Initiation (0 to < 4 months previous therapy for Siliq) When a benefit, initiation of Siliq may be approved when all of the following criteria are met (i., ii., and iii.): i. Siliq is to be used for the treatment of adults with moderate to severe psoriasis. ii. One of the following criterion is met (a. or b.): a. Treatment with systemic therapy and phototherapy (e.g. PUVA, UVB) was ineffective or not tolerated. If member is not a candidate for phototherapy treatment (e.g. phototherapy is contraindicated due to history of lupus erythematosus, porphyria, or xeroderma pigmentosum), treatment with systemic therapy (e.g. methotrexate, cyclosporine) must have been ineffective or not tolerated, or all systemic therapies are contraindicated. b. Treatment with systemic therapy (e.g. methotrexate, cyclosporine) was ineffective or not tolerated, or all systemic therapies are contraindicated. iii. Treatment with at least two preferred biologic products for the treatment of psoriasis was ineffective or not tolerated (see Table 1). Maintenance (≥ 4 months previous therapy for Siliq) When a benefit, maintenance of Siliq may be approved when all of the following criteria are met (i. through iv.): i. Siliq is to be used for the treatment of adults with moderate to severe psoriasis. ii. One of the following criterion is met (a. or b.): a. Treatment with systemic therapy and phototherapy (e.g. PUVA, UVB) was ineffective or not tolerated. If member is not a candidate for phototherapy treatment (e.g. phototherapy is contraindicated due to history of lupus erythematosus, porphyria, or xeroderma pigmentosum), treatment with systemic therapy (e.g. methotrexate, cyclosporine) must have been ineffective or not tolerated, or all systemic therapies are contraindicated. b. Treatment with systemic therapy (e.g. methotrexate, cyclosporine) was ineffective or not tolerated, or all systemic therapies are contraindicated. iii. Treatment with at least two preferred biologic products for the treatment of psoriasis was ineffective or not tolerated (see Table 1). iv. Improvement in the physician's global assessment score, psoriasis area severity index score, or a decrease in the affected body surface area of psoriatic plaque lesions has been documented.
B. Reauthorization When a benefit, reauthorization of Siliq may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
C. Quantity Limitations When prior authorization is approved, Siliq may be authorized in quantities as follows:
XVI. Simponi (golimumab) A. Initial Authorization 1. Rheumatoid Arthritis When a benefit, coverage of Simponi SC may be approved for rheumatoid arthritis (RA) when all of the following criteria are met (a., b., and c.): a. Simponi 50 mg is to be used for the treatment of adults with rheumatoid arthritis (RA) in combination with methotrexate. b. Treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. c. Treatment with at least two preferred biologic products for the treatment of rheumatoid arthritis was ineffective or not tolerated (see Table 1). 2. Ankylosing Spondylitis When a benefit, coverage of Simponi SC may be approved for ankylosing spondylitis (AS) when all of the following criteria are met (a., b., and c.): a. Simponi 50 mg is to be used for the treatment of adults with ankylosing spondylitis. b. Treatment with a nonsteroidal anti-inflammatory drug (NSAID) was ineffective or not tolerated, or all NSAIDs are contraindicated. c. Treatment with at least two preferred biologic products for the treatment of ankylosing spondylitis was ineffective or not tolerated (see Table 1) 3. Psoriatic Arthritis When a benefit, coverage of Simponi SC 50 mg may be approved for psoriatic arthritis (PsA) when one of the following criterion is met (a., b., or c.): a. Spinal or axial psoriatic arthritis (i., ii., and iii.): i. For the treatment of adults with predominant spinal or axial psoriatic arthritis. ii. When treatment with at least one NSAID was ineffective or not tolerated or all NSAIDs are contraindicated. iii. Treatment with at least two preferred biologic products for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1). b. Psoriatic arthritis without spinal or axial disease (i., ii., and iii.): i. For the treatment of adults with psoriatic arthritis without spinal disease ii. When treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. iii. Treatment with at least two preferred biologic products for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1). c. Enthesitis and/or dactylitis associated psoriatic arthritis (i., ii., and iii.): i. For the treatment of adults with active enthesitis and/or dactylitis associated with psoriatic arthritis. ii. When treatment with (a. or b.): a. At least one NSAID or a local glucocorticoid injection was ineffective or not tolerated. b. All NSAIDs and all local glucocorticoid injections are contraindicated. iii. Treatment with at least two preferred biologic products for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1). 4. Ulcerative Colitis When a benefit, coverage of Simponi SC may be approved for adults patients with ulcerative colitis (UC) when all of the following criteria are met (a. and b.): a. Simponi 100 mg is to be used to induce and maintain clinical remission in adult patients with moderate to severe ulcerative colitis and one of the following (i., ii., or iii.): i. Treatment with at least two immunosuppressants (e.g. corticosteroids, azathioprine, 6-mercaptopurine) was ineffective or not tolerated. ii. The member requires continuous steroid therapy. iii. The member is currently pregnant. b. Treatment with preferred biologic product (Humira) for the treatment of ulcerative colitis was ineffective or not tolerated (see Table 1).
B. Reauthorization When a benefit, reauthorization of Simponi SC may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
C. Quantity Limitations When prior authorization is approved, Simponi SC may be authorized in quantities as follows:
XVII. Taltz (ixekizumab) A. Initial Authorization 1. Psoriatic Arthritis When a benefit, coverage of Taltz may be approved for psoriatic arthritis (PsA) when one of the following criteria are met (a., b., or c.): a. Spinal or axial psoriatic arthritis (i., ii., and iii.): i. For the treatment of adults with predominant spinal or axial psoriatic arthritis. ii. When treatment with at least one NSAID was ineffective or not tolerated or all NSAIDs are contraindicated. iii. Treatment with at least two preferred biologic products for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1). b. Psoriatic arthritis without spinal or axial disease (i., ii., and iii.): i. For the treatment of adults with psoriatic arthritis without spinal disease ii. When treatment with at least one nonbiologic DMARD (e.g. methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, cyclosporine) was ineffective or not tolerated, or all nonbiologic DMARDs are contraindicated. iii. Treatment with at least two preferred biologic products for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1). c. Enthesitis and/or dactylitis associated psoriatic arthritis (i., ii., and iii.): i. For the treatment of adults with active enthesitis and/or dactylitis associated with psoriatic arthritis. ii. When treatment with (a. or b.): a. At least one NSAID or a local glucocorticoid injection was ineffective or not tolerated. b. All NSAIDs and all local glucocorticoid injections are contraindicated. iii. Treatment with at least two preferred biologic products for the treatment of psoriatic arthritis was ineffective or not tolerated (see Table 1). 2. Plaque Psoriasis When a benefit, coverage of Taltz may be approved for chronic plaque psoriasis (PsO) when all of the following criteria are met (a., b., and c.): a. Taltz is to be used for the treatment of adults with moderate to severe psoriasis b. One of the following criterion is met (i. or ii.): i. Treatment with phototherapy (e.g. PUVA, UVB) was ineffective or not tolerated. If member is not a candidate for phototherapy treatment (e.g. phototherapy is contraindicated due to history of lupus erythematosus, porphyria, or xeroderma pigmentosum), treatment with systemic therapy (e.g. methotrexate, cyclosporine) must have been ineffective or not tolerated, or all systemic therapies are contraindicated. ii. Treatment with systemic therapy (e.g. methotrexate, cyclosporine) was ineffective or not tolerated, or all systemic therapies are contraindicated. c. Treatment with at least two preferred biologic products for the treatment of plaque psoriasis was ineffective or not tolerated (see Table 1).
B. Reauthorization When a benefit, reauthorization of Taltz may be approved when the following criterion is met (1.): 1. Clinical documentation of disease stability or improvement must be provided.
C. Quantity Limitations When prior authorization is approved, Taltz may be authorized in quantities as follows:
I. If the patient has already had a trial of at least one biologic agent the patient is not required to “step back” and try a nonbiologic agent. II. For Commercial and HCR members enrolled in a West Virginia Plan, an exception to the step therapy within this policy may be made based on Policy J-513 – West Virginia – Step Therapy Override Exception – Commercial and Healthcare Reform. |
| Limitations of Coverage |
|---|
|
I. For Commercial and HCR members, coverage of the Chronic Inflammatory Disease (CID) medication for disease states outside of their FDA-approved indications should be denied based on the lack of clinical data to support their effectiveness and safety in other conditions. II. For Commercial and HCR members with a closed formulary, a non-formulary product will only be approved if the member meets the criteria for a formulary exception in addition to the criteria outlined within this policy. |
| Authorization Duration |
|---|
|
Initial Authorization
Reauthorization
|
| Automatic Approval Criteria |
|---|
|
None
|
| Version: J-0558-011 |
| Effective Date Begin: 05/02/2019 |
| Effective End Begin: 08/07/2019 |
| Original Date: 07/15/2017 |
| Review Date: 05/01/2019 |
References:
- Actemra [package insert]. San Francisco, CA: Genentech; September 2018.
- Cosentyx [package insert]. East Hanover, NJ: Novartis; January 2018.
- Langley R., Eleweksi B, Lebwhol M et al. Secukinumab in plaque Psoriasis. Results of Two Phase 3 trials. N Engl J Med. 2014 July 24; 371:326-338.
- Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation; October 2018.
- Takei S, Groh D, Bernstein B, et al: Safety and efficacy of high dose etanercept in treatment of juvenile rheumatoid arthritis. J Rheumatol 2001; 28(7):1677-1680.
- Leonardi CL, Powers JL, Matheson RT, et al: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349(21):2014-2022.
- Gorman JD, Sack KE, & Davis JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346(18):1349-1356.
- Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as Monotherapy in Patients with Psoriasis. N Engl J Med. 2003;349: 2014-2022.
- Humira [package insert]. North Chicago, IL: AbbVie, Inc.; October 2018.
- Colombel JF, Sandborn WJ, Rutgeerts P, et al: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132(1):52-65.
- Gladman DD, Mease PJ, Cifaldi MA, et al: Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 2007; 66(2):163-168.
- Gordon KB, Langley RG, Leonardi C, et al: Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55(4):598-606.
- Mease PJ, Gladman DD, Ritchlin CT, et al: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52(10):3279-3289.
- Menter A, Tyring SK, Gordon K, et al: Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58(1):106-115.
- Otezla [package insert]. Summit, NJ: Celgene; June 2017.
- Stelara [package insert]. Horsham, PA: Janssen; June 2018.
- Peters BP, Weissman FG, Gill MA. Pathophysiology and treatment of psoriasis. Am J Health Sys Pharm. 2000; 57: 645-662.
- Griffiths CE , Strober BE , van de,Kerkhof P. , et al: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362(2):118-128.
- Leonardi CL, Kimball AB, Papp KA, et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371(9625):1665-1674.
- Papp KA, Langley RG, Lebwohl M, et al: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371(9625):1675-1684.
- Xeljanz [package insert]. New York, NY: Pfizer, Inc.; August 2018.
- Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010; 7:41.
- Cimzia [package insert]. Smyrna, GA: UCB, Inc.; March 2019.
- Sandborn W., Feagan B., Stoinov S. et al. Certolizumab pegol for the treatment of Crohn’s disease. N Eng J Med 2007; 357:228-38.
- Schreiber S., Kareemi M., Lawrence I. et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Eng J Med 2007; 357:239-50.
- Kevzara [package insert]. Bridgewater, NJ and Tarrytown, NY: Sanofi-Aventis and Regeneron. April 2018.
- Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study (MOBILITY). Arthritis Rheumatol. 2015 Jun;67(6):1424-37.
- Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors (TARGET). Arthritis Rheumatol. 2017 Feb;69(2):277-290.
- Kineret [package insert]. Waltham, MA: SOBI, Inc. (Swedish Orphan Biovitrum); June 2018.
- Jiang Y, Genant HK, Watt I, et al: A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43(5):1001-1009.
- Jiang Y, Genant HK, Watt I, et al: A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000a; 43(5):1001-1009.
- Olumiant [package insert]. Indianapolis, IN: Eli Lilly. May 2018.
- Orencia [package insert]. Princeton, NJ: Bristol-Myers Squibb; June 2017.
- Siliq [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals International: February 2017.
- Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. NEJM 373(Oct). 2015:1318-1328.
- Simponi [package insert]. Horsham, PA: Janssen; March 2018.
- Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47(3):383-396.
- Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; May 2018.
- Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386: 541-51.
- Tremfya [package insert]. Horsham, PA: Janssen; July 2017.
- Skyrizi [package insert]. North Chicago, IL: AbbVie, Inc.; April 2019.
- Singh, Jasvinder A, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatol Jan (68) (2016):1-26.
- Braun, J. von, et al. "2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis." Annals of the rheumatic diseases6 (2011): 896-904.
- Lichtenstein GR, Loftus EV, Isaacs KL, et al. The American College of Gastroenterology Guidelines - Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018; 113: 481-517.
- Kornbluth A, Sachar DB. The American College of Gastroenterology Guidelines - Ulcerative Colitis Practice Guidelines in Adults. Am J Gastroenterol. 2010; 105:501-523.
- Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. Journal of the American Academy of Dermatology5 (2008):826-50.
- Gottlieb, Alice, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. Journal of the American Academy of Dermatology 58.5 (2008): 851-864.
- Ringold S, Weiss PF, Colbert RA et al. Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment plans New Onset Polyarticular Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). 2014. July; 66(7):1063-72.
- Menter A., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. Volume 62, Number 1.
- Mahadevan Uma, et al. Inflammatory Bowel Diseases in Pregnancy Clinical Care Pathway: A Report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. Available at: https://www.gastrojournal.org/article/S0016-5085(18)35437-4/fulltext. Accessed March 1, 2019.
- Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-72.
 |
Pharmacy policies do not constitute medical advice, nor are they intended to govern physicians' prescribing or the practice of medicine. They are intended to reflect Highmark's coverage and reimbursement guidelines. Coverage may vary for individual members, based on the terms of the benefit contract.
Highmark retains the right to review and update its pharmacy policy at its sole discretion. These guidelines are the proprietary information of Highmark. Any sale, copying or dissemination of the pharmacy policies is prohibited; however, limited copying of pharmacy policies is permitted for individual use.
